Compositions comprising glucagon analogs and methods of making and using the same
AssigneeLongevity Biotech, Inc.
InventorsScott Shandler, Samuel H. Gellman
Life of this patent
Estimating the term…
Abstract
This invention relates to novel compositions comprising analogs of glucagon, wherein the analog comprises an α-amino acid and at least one β-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways, including diabetes and other metabolic disorders. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.
Claims18
A peptide comprising the amino acid sequence YXEGTFTSDYSIYLDKQAAXEFVNWLLA (SEQ ID NO:
- 168) or a pharmaceutically acceptable salt thereof;
- wherein X is the amino acid α-aminoisobutyric acid (Aib);
- wherein at least four alpha amino acids in the amino acid sequence of the peptide are replaced with cyclic beta amino acids;
- and
- wherein the peptide comprises at least two contiguous patterns of alpha and beta amino acids chosen from:
- βαααβαα, αβαααβα, and ααβαααβ.
A peptide that comprises an amino acid sequence that is at least 96% homologous to YXEGTFTSDYSIYLDKX1AAXX1FVX2WLLX1G (SEQ ID NO:41) or a pharmaceutically acceptable salt thereof;
- wherein X is the amino acid α-aminoisobutyric acid (Aib), wherein X1 is the cyclic beta amino acid
- ACPC and X2 is the cyclic beta amino acid
- APC.
Dependencies are inferred from the claim text.